TWI622394B - 用於治療高膽固醇血症之方法 - Google Patents
用於治療高膽固醇血症之方法 Download PDFInfo
- Publication number
- TWI622394B TWI622394B TW103130375A TW103130375A TWI622394B TW I622394 B TWI622394 B TW I622394B TW 103130375 A TW103130375 A TW 103130375A TW 103130375 A TW103130375 A TW 103130375A TW I622394 B TWI622394 B TW I622394B
- Authority
- TW
- Taiwan
- Prior art keywords
- mammal
- hypercholesterolemia
- fat
- density lipoprotein
- concentration
- Prior art date
Links
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title abstract description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 54
- 241000124008 Mammalia Species 0.000 claims abstract description 41
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 239000008280 blood Substances 0.000 claims abstract description 24
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 22
- 108010010234 HDL Lipoproteins Proteins 0.000 claims abstract description 19
- 102000015779 HDL Lipoproteins Human genes 0.000 claims abstract description 19
- 108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 19
- 102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 19
- 108010004103 Chylomicrons Proteins 0.000 claims abstract description 9
- UYEWRTKHKAVRDI-UHFFFAOYSA-N Calebin A Natural products C1=C(O)C(OC)=CC(C=CC(=O)COC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-UHFFFAOYSA-N 0.000 claims abstract description 4
- UYEWRTKHKAVRDI-ASVGJQBISA-N Calebin A Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)COC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-ASVGJQBISA-N 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 6
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 9
- 235000019197 fats Nutrition 0.000 description 36
- 235000009200 high fat diet Nutrition 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 29
- 238000012360 testing method Methods 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- YRTMFXIMEWYCDX-UHFFFAOYSA-N CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CCNCC Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CCNCC YRTMFXIMEWYCDX-UHFFFAOYSA-N 0.000 description 1
- YZJARFWVCIXVDT-UHFFFAOYSA-N Caribine Natural products C1CCNC2C(C34)C5=CC(OCO6)=C6C=C5CN3CC(O)C4=CC21 YZJARFWVCIXVDT-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 206010048255 Zieve syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/259,404 | 2014-04-23 | ||
| US14/259,404 US9668999B2 (en) | 2014-04-23 | 2014-04-23 | Method for the treatment of hypercholesterolemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201540295A TW201540295A (zh) | 2015-11-01 |
| TWI622394B true TWI622394B (zh) | 2018-05-01 |
Family
ID=50828681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103130375A TWI622394B (zh) | 2014-04-23 | 2014-09-03 | 用於治療高膽固醇血症之方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9668999B2 (https=) |
| EP (1) | EP2937084B1 (https=) |
| JP (1) | JP6263707B2 (https=) |
| KR (1) | KR101647549B1 (https=) |
| AU (1) | AU2014202312B2 (https=) |
| CA (2) | CA2850999C (https=) |
| EA (1) | EA027148B1 (https=) |
| MY (1) | MY170067A (https=) |
| PH (1) | PH12014000244A1 (https=) |
| PL (1) | PL2937084T3 (https=) |
| TW (1) | TWI622394B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503805XA (en) * | 2015-04-19 | 2016-11-29 | Sabinsa Corp | Calebin A For Hepatic Steatosis |
| US9539232B1 (en) * | 2016-08-04 | 2017-01-10 | Muhammed Majeed | Calebin A for osteoporosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013109241A1 (en) * | 2011-01-10 | 2013-07-25 | Muhammed Majeed | Anti-obesity potential of calebin a |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060352C (zh) * | 1996-02-08 | 2001-01-10 | 袁克兴 | 降脂药及其制备方法 |
| US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
| AU2300001A (en) * | 1999-10-22 | 2001-05-08 | Board Of Trustees Of The University Of Illinois, The | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| US20020012733A1 (en) | 2000-04-12 | 2002-01-31 | The Procter & Gamble Company | Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels |
| JP2005232059A (ja) * | 2004-02-18 | 2005-09-02 | Iichiro Shimomura | 低アディポネクチン血症予防・治療剤 |
| JP4834824B2 (ja) * | 2004-07-08 | 2011-12-14 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
| JP2010018522A (ja) * | 2007-03-23 | 2010-01-28 | Hiroshima Univ | アディポネクチン産生促進剤 |
| JP5294165B2 (ja) * | 2007-03-23 | 2013-09-18 | ナガセケムテックス株式会社 | アディポネクチン上昇剤 |
| CN101301455A (zh) * | 2008-07-01 | 2008-11-12 | 崔井朝 | 一种治疗高脂血症的中药复方姜黄固体分散体 |
| JP2011063543A (ja) * | 2009-09-17 | 2011-03-31 | Kao Corp | アディポネクチン増加剤 |
-
2014
- 2014-04-23 US US14/259,404 patent/US9668999B2/en active Active
- 2014-04-29 AU AU2014202312A patent/AU2014202312B2/en not_active Ceased
- 2014-05-01 CA CA2850999A patent/CA2850999C/en active Active
- 2014-05-01 CA CA2963383A patent/CA2963383C/en active Active
- 2014-05-02 JP JP2014095457A patent/JP6263707B2/ja not_active Expired - Fee Related
- 2014-05-08 EP EP14167512.4A patent/EP2937084B1/en active Active
- 2014-05-08 PL PL14167512T patent/PL2937084T3/pl unknown
- 2014-06-10 KR KR1020140070179A patent/KR101647549B1/ko not_active Expired - Fee Related
- 2014-07-25 MY MYPI2014002207A patent/MY170067A/en unknown
- 2014-08-26 PH PH12014000244A patent/PH12014000244A1/en unknown
- 2014-09-03 TW TW103130375A patent/TWI622394B/zh not_active IP Right Cessation
- 2014-09-17 EA EA201491545A patent/EA027148B1/ru unknown
-
2015
- 2015-03-03 US US14/637,081 patent/US9610273B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013109241A1 (en) * | 2011-01-10 | 2013-07-25 | Muhammed Majeed | Anti-obesity potential of calebin a |
Non-Patent Citations (3)
| Title |
|---|
| EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 591, no. 1-3 |
| Mol. Nutr. Food Res. 2013, 57, 1510-1528 |
| Mol. Nutr. Food Res. 2013, 57, 1510-1528 EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 591, no. 1-3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9610273B2 (en) | 2017-04-04 |
| CA2963383A1 (en) | 2015-10-23 |
| EP2937084B1 (en) | 2016-11-30 |
| US20150306060A1 (en) | 2015-10-29 |
| US20150306059A1 (en) | 2015-10-29 |
| PL2937084T3 (pl) | 2017-05-31 |
| US9668999B2 (en) | 2017-06-06 |
| TW201540295A (zh) | 2015-11-01 |
| EA201491545A1 (ru) | 2015-10-30 |
| MY170067A (en) | 2019-07-03 |
| EA027148B1 (ru) | 2017-06-30 |
| JP6263707B2 (ja) | 2018-01-24 |
| CA2963383C (en) | 2018-12-04 |
| JP2015209424A (ja) | 2015-11-24 |
| KR101647549B1 (ko) | 2016-08-10 |
| AU2014202312B2 (en) | 2018-02-22 |
| HK1210590A1 (en) | 2016-04-29 |
| CA2850999C (en) | 2018-04-03 |
| CA2850999A1 (en) | 2015-10-23 |
| PH12014000244B1 (en) | 2016-08-08 |
| EP2937084A1 (en) | 2015-10-28 |
| NZ624269A (en) | 2014-12-24 |
| KR20150122552A (ko) | 2015-11-02 |
| AU2014202312A1 (en) | 2015-11-12 |
| PH12014000244A1 (en) | 2016-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Kerschaver et al. | Reducing weaning stress in piglets by pre-weaning socialization and gradual separation from the sow: a review | |
| Zhou et al. | Maternal genistein intake mitigates the deleterious effects of high-fat diet on glucose and lipid metabolism and modulates gut microbiota in adult life of male mice | |
| Li et al. | Epigallocatechin gallate reduces uric acid levels by regulating xanthine oxidase activity and uric acid excretion in vitro and in vivo | |
| Gao et al. | Molecular mechanisms and regulatory factors governing feed utilization efficiency in laying hens: Insights for sustainable poultry production and breeding optimization | |
| Zheng et al. | Comparison of artificial feed and natural food by the growth and blood biochemistry in Chinese sturgeon Acipenser sinensis | |
| TWI622394B (zh) | 用於治療高膽固醇血症之方法 | |
| Lin et al. | Dietary supplementation of 25-hydroxycholecalciferol improves livability in broiler breeder hens-amelioration of cardiac pathogenesis and hepatopathology | |
| Jin et al. | Effects of zinc source and level on the intestinal immunity of xueshan chickens under heat stress | |
| CN112119977B (zh) | Cd317诱导的抑郁和记忆损伤的小鼠模型的构建方法及其应用 | |
| Elbaz et al. | Feed withdrawal coupled with classical conditioning modifies the behavioral, physiological, and productive traits in Japanese quail (Coturnix Coturnix japonica) | |
| Krauze et al. | Assessment of neurodegenerative changes in turkeys fed diets with different proportions of arginine and methionine relative to lysine | |
| Tomaszewska et al. | The protective role of alpha-ketoglutaric acid on the growth and bone development of experimentally induced perinatal growth-retarded piglets | |
| Du et al. | Hepatic transcriptome reveals potential key genes contributing to differential milk production | |
| Díaz et al. | The probiotic Pediococcus acidilactici in the feed of Salmonids: a strategy to improve reproductive parameters | |
| Ragab et al. | Black Maca (Lepidium meyenii Walp.) Hydroalcoholic Extract as an Ameliorating Agent against Heat Stress Conditions of V-Line Rabbit Does | |
| Arévalo Sureda et al. | Isoquinoline alkaloids in sows’ diet reduce body weight loss during lactation and increase igg in colostrum | |
| Pompeo et al. | Risk factors for mortality in patients with sickle cell disease: an integrative review | |
| Mekuria et al. | Cardioprotective effects of insect Apis melifera based complementary foods using an in-vivo white albino (BALB/c) mice | |
| AL-Khafaji | Investigation of some Biochemical and histopathological changes in liver and kidney of diet induced obesity in male albino mice treated with rosuvastatin | |
| Zhu et al. | Investigation of Off-Season Breeding Effects on Egg-Laying Performance, Serum Biochemical Parameters, and Reproductive Hormones in Zhedong White | |
| HK1210590B (en) | Method for the treatment of hypercholesterolemia | |
| CN118235740B (zh) | 一种通过向饲料中添加异戊酸钠缓解慢性束缚应激对动物不良影响的方法 | |
| Kundu et al. | Biochemical and cellular (liver and kidney) restorative properties of garlic (Allium sativum) aqueous extract in cow brain-induced hypercholesterolemic model Swiss albino mice | |
| Du et al. | Hepatic Transcriptome Reveals Potential Key Genes Contributing to Differential Milk Production. Genes 2024, 15, 1229. h ps | |
| NZ624269B (en) | Method for the treatment of hypercholesterolemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |